BusinessMinerva Neurosciences Reports Fiscal 2016 Fourth Quarter and Year End Financial Results and Business UpdatesBy Nasdaq OMXMar 13, 2017, 11:30 AM UTC
BusinessMinerva Neurosciences to Report Fiscal 2016 Fourth Quarter and Year End Financial Results and Business Updates on March 13, 2017By Nasdaq OMXMar 6, 2017, 1:30 PM UTC
BusinessMinerva Neurosciences to Host R&D Day Focused on Unmet Needs and Emerging Treatment Strategies in SchizophreniaBy Nasdaq OMXFeb 21, 2017, 1:30 PM UTC
BusinessMinerva Neurosciences Names Michael Davidson, M.D. as Chief Medical OfficerBy Nasdaq OMXDec 20, 2016, 1:30 PM UTC
BusinessMinerva Neurosciences’ Clinical Data Featured at The American College of Neuropsychopharmacology Annual MeetingBy Nasdaq OMXDec 5, 2016, 1:00 PM UTC
BusinessMinerva Neurosciences Reports Third Quarter 2016 Financial Results and Business UpdatesBy Nasdaq OMXNov 3, 2016, 11:30 AM UTC
BusinessMinerva Neurosciences Announces Positive Data From Six-Month Extension of Phase IIb Trial of MIN-101 Monotherapy in SchizophreniaBy Nasdaq OMXOct 26, 2016, 12:30 PM UTC
BusinessMinerva Neurosciences Announces Acceptance of Presentations of Clinical Data With MIN-101 and MIN-117 at American College of Neuropsychopharmacology Annual MeetingBy Nasdaq OMXOct 13, 2016, 12:30 PM UTC
